VBLT NASDAQ
Vascular Biogenics Ltd.
1W: -34.2%
1M: -33.8%
3M: -44.2%
1Y: +13.0%
3Y: -87.6%
5Y: -89.2%
$0.16
Last traded 2023-10-16 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$658K
-14.3% ▼
5Y CAGR: -45.6%
Gross Profit
$554K
+37.5% ▲
5Y CAGR: -47.2%
Operating Income
-$33M
-9.5% ▼
Net Income
-$32M
-12.2% ▼
EPS (Diluted)
$-0.42
-2.4% ▼
EBITDA
-$31M
-4.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $585K | $562K | $922K | $768K | $658K |
| YoY Growth | -95.8% | -3.9% | +64.1% | -16.7% | -14.3% |
| Cost of Revenue | $235K | $163K | $394K | $365K | $104K |
| Gross Profit | $350K | $399K | $528K | $403K | $554K |
| Gross Margin | 59.8% | 71.0% | 57.3% | 52.5% | 84.2% |
| R&D Expenses | $16M | $15M | $20M | $23M | $22M |
| SG&A Expenses | $6M | $5M | $5M | $8M | $12M |
| Operating Expenses | $22M | $20M | $25M | $30M | $33M |
| Operating Income | -$21M | -$20M | -$24M | -$30M | -$33M |
| Operating Margin | -3625.1% | -3561.2% | -2655.4% | -3905.7% | -4992.9% |
| Interest Expense | $0 | $313K | $105K | $44K | $85K |
| Income Before Tax | -$20M | -$19M | -$24M | -$30M | -$32M |
| Tax Expense | $0 | $313K | $105K | -$1M | -$85K |
| Net Income | -$20M | -$20M | -$24M | -$29M | -$32M |
| Net Margin | -3497.1% | -3517.8% | -2638.8% | -3738.0% | -4896.5% |
| EPS (Diluted) | $-0.62 | $-0.55 | $-0.56 | $-0.41 | $-0.42 |
| EBITDA | -$20M | -$17M | -$23M | -$30M | -$31M |
| Shares Outstanding | 33M | 36M | 44M | 69M | 78M |